Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Production of insulin secreting cells derived from induced pluripotent stem cells for the treatment of Type 1 diabetes mellitus by cellular replacement therapy.
FY 2009-10
Summary
Type 1 diabetes mellitus is a widespread disease that could potentially be treated through regenerative medicine. A promising treatment strategy is to transplant replacement cells capable of insulin production and secretion. By replacing these cells it should be possible to restore normal insulin function for diabetics. Unfortunately, using donor cells is a problem because of rejection of the introduced cells, and because of a lack of donors. To solve this problem it has been proposed that stem cells could be used as a source of transplant cells, specifically a class of stem cells called induced pluripotent stem cells (iPSC). The advantage of iPSCs is that they can be made from a cell that is already differentiated and then can be transformed into an insulin secreting cell by providing the appropriate growth conditions. This approach has the potential to produce patient specific stem cells, thereby eliminating the problem of transplant rejection. Currently, a method of creating iPSCs that are potentially safe for human therapy does exist, but it has not been shown that these iPSCs cells can be transformed into insulin secreting cells. This research proposal describes a project to determine whether creating insulin producing cells from iPSCs is possible, and based on the literature reviewed it seems that this goal is achievable. However, in order for iPSC derived insulin secreting cells to be an effective therapy for Type 1 diabetes mellitus insulin needs to be secreted in amounts similar to normal human insulin cells. Therefore, the second goal of this project is to optimize the transformation of iPSCs into insulin secreting cells that are suitable for cellular transplantation and the treatment of diabetes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
199307
Name
Glew Riley A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Production of insulin secreting cells derived from induced pluripotent stem cells for the treatment of Type 1 diabetes mellitus by cellular replacement therapy.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cellular Therapeutics; Developmental Biology; Differentiation; Regenerative Medicine; Stem Cells
Abstract
Type 1 diabetes mellitus is a widespread disease that could potentially be treated through regenerative medicine. A promising treatment strategy is to transplant replacement cells capable of insulin production and secretion. By replacing these cells it should be possible to restore normal insulin function for diabetics. Unfortunately, using donor cells is a problem because of rejection of the introduced cells, and because of a lack of donors. To solve this problem it has been proposed that stem cells could be used as a source of transplant cells, specifically a class of stem cells called induced pluripotent stem cells (iPSC). The advantage of iPSCs is that they can be made from a cell that is already differentiated and then can be transformed into an insulin secreting cell by providing the appropriate growth conditions. This approach has the potential to produce patient specific stem cells, thereby eliminating the problem of transplant rejection. Currently, a method of creating iPSCs that are potentially safe for human therapy does exist, but it has not been shown that these iPSCs cells can be transformed into insulin secreting cells. This research proposal describes a project to determine whether creating insulin producing cells from iPSCs is possible, and based on the literature reviewed it seems that this goal is achievable. However, in order for iPSC derived insulin secreting cells to be an effective therapy for Type 1 diabetes mellitus insulin needs to be secreted in amounts similar to normal human insulin cells. Therefore, the second goal of this project is to optimize the transformation of iPSCs into insulin secreting cells that are suitable for cellular transplantation and the treatment of diabetes.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Glew, Riley A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~